VSTM: Verastem, Inc.
About
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
Current Value
$3.961 Year Return
Current Value
$3.961 Year Return
Key Details
Market Cap
$176.25M
P/E Ratio
-1.24
1Y Stock Return
-36.94%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
14.4
Strategies that include VSTM
Stock's related to VSTM
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| WDAY | 38.58% | $69.13B | +9.81% | 0.00% |
| GBIO | 30.77% | $92.84M | +20.87% | 0.00% |
| EDIT | 28.47% | $204.72M | -75.49% | 0.00% |
| ATNM | 28.43% | $44.30M | -67.05% | 0.00% |
| TARS | 27.38% | $1.79B | +166.88% | 0.00% |
| DVAX | 27.23% | $1.58B | -11.37% | 0.00% |
| CRBU | 26.88% | $180.20M | -62.45% | 0.00% |
| ENS | 26.53% | $3.75B | +6.54% | 0.97% |
| RDFN | 26.37% | $1.01B | +24.16% | 0.00% |
| ARCT | 26.24% | $489.20M | -21.27% | 0.00% |
| CERS | 26.17% | $312.00M | -0.59% | 0.00% |
| BCPC | 26.14% | $5.77B | +45.27% | 0.45% |
| RCKT | 26.10% | $1.20B | -39.83% | 0.00% |
| AYI | 25.95% | $9.78B | +75.10% | 0.19% |
| TKR | 25.52% | $5.15B | +0.82% | 1.84% |
| KOD | 25.52% | $296.80M | +150.67% | 0.00% |
| OPEN | 25.47% | $1.14B | -31.62% | 0.00% |
| IOVA | 25.37% | $2.50B | +58.41% | 0.00% |
| RPRX | 25.35% | $11.56B | -3.67% | 3.22% |
| CDMO | 25.33% | $779.62M | +122.04% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MPAA | -<0.01% | $134.99M | -29.46% | 0.00% |
| ALL | <0.01% | $52.06B | +45.67% | 1.85% |
| POWL | <0.01% | $3.74B | +275.35% | 0.29% |
| KMB | 0.01% | $45.22B | +11.57% | 3.58% |
| SD | -0.02% | $430.19M | -10.98% | 3.79% |
| SPR | -0.02% | $3.72B | +23.27% | 0.00% |
| CRVO | -0.03% | $83.20M | +2.86% | 0.00% |
| SMR | 0.04% | $2.73B | +989.52% | 0.00% |
| NLOP | -0.08% | $458.04M | +94.60% | 0.00% |
| GOLF | 0.09% | $4.21B | +20.68% | 1.22% |
| JPM | 0.09% | $684.38B | +58.91% | 1.89% |
| EOG | -0.10% | $76.03B | +10.19% | 2.70% |
| UNM | 0.10% | $13.16B | +69.20% | 2.16% |
| WRB | -0.11% | $22.94B | +29.98% | 0.69% |
| PR | -0.11% | $10.64B | +15.08% | 3.02% |
| T | -0.11% | $163.09B | +40.40% | 4.87% |
| OCSL | -0.12% | - | - | 14.23% |
| LITB | -0.12% | $35.48M | -75.45% | 0.00% |
| OPRA | 0.13% | $1.75B | +63.06% | 4.03% |
| OPRX | 0.16% | $75.16M | -58.02% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CCEC | -16.98% | $1.02B | +28.03% | 3.26% |
| SOC | -15.59% | $1.93B | +74.70% | 0.00% |
| LPLA | -13.67% | $23.55B | +38.13% | 0.38% |
| BEST | -13.62% | $31.65M | +3.88% | 0.00% |
| DECK | -12.97% | $26.78B | +66.79% | 0.00% |
| ROST | -12.87% | $46.20B | +6.53% | 1.05% |
| BG | -11.29% | $12.50B | -17.29% | 3.02% |
| IMO | -10.10% | $39.72B | +31.84% | 2.23% |
| CB | -9.95% | $114.43B | +26.00% | 1.24% |
| HUSA | -9.94% | $16.69M | -11.56% | 0.00% |
| KNOP | -9.66% | $210.40M | +11.75% | 1.68% |
| TTE | -9.57% | $138.45B | -11.95% | 5.50% |
| CVE | -8.99% | $29.32B | -10.19% | 2.95% |
| AFL | -8.91% | $61.74B | +35.69% | 1.35% |
| GIL | -8.84% | $7.55B | +37.20% | 1.63% |
| SU | -8.57% | $52.05B | +23.58% | 3.92% |
| CME | -8.57% | $82.76B | +9.21% | 1.98% |
| BJ | -8.47% | $11.45B | +32.57% | 0.00% |
| GHI | -8.32% | $272.26M | -27.60% | 12.75% |
| GTE | -8.25% | $225.69M | -1.28% | 0.00% |
ETF's related to VSTM
News
Yahoo
NEEDHAM, Mass. AP) — Verastem Inc. VSTM) on Wednesday reported a loss of $24 million in its third quarter.
Yahoo
BOSTON, November 06, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the third quarter ended September 30, 2024.
Yahoo
The NDA was submitted under the FDA's accelerated approval pathway.
Yahoo
BOSTON, October 31, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has completed its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational and potential first-in-class combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral selective FAK inhibitor, for adults with recurrent KRAS mutant low-grade serous ovarian
Yahoo
BOSTON, October 31, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences:
Finnhub
BOSTON - Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from the Phase 2 RAMP 201 clinical trial...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.